Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Interpersonal Psychotherapy01:25

Interpersonal Psychotherapy

Interpersonal psychotherapy (IPT) is a structured, time-limited therapeutic approach initially developed to treat depression. It integrates key concepts from psychodynamic, humanistic, and cognitive-behavioral therapies, making it a uniquely eclectic framework. The therapy is rooted in the interpersonal theories of Adolph Meyer and Harry Stack Sullivan, as well as John Bowlby's attachment theory, and focuses on the interplay between interpersonal relationships and emotional well-being.
iPS Cell Differentiation01:22

iPS Cell Differentiation

The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
EPS and iPS Cells in Disease Research01:21

EPS and iPS Cells in Disease Research

Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prevalence, detection, and trajectory of combined pulmonary fibrosis and emphysema.

Chest·2026
Same author

[Comparative analysis of drug therapy for fibrotic interstitial lung diseases based on results of phase 3 study].

Pneumologie (Stuttgart, Germany)·2026
Same author

Benchmarking DNA barcode decoding strategies under high error rates.

BMC bioinformatics·2026
Same author

Clinical and Radiologic Characteristics of Familial Pulmonary Fibrosis.

Annals of the American Thoracic Society·2026
Same author

Eosinophilic Pleural Effusion Following Long-Term Asthma Remission Under Dupilumab Therapy: A Search for Clues Using Cytokine Analyses.

Journal of investigational allergology & clinical immunology·2026
Same author

Impact of gastroesophageal reflux and proton pump inhibitors in fibrotic interstitial lung disease.

Respiratory medicine·2026

Related Experiment Video

Updated: Jun 18, 2026

Refined Murine Model of Idiopathic Pulmonary Fibrosis
07:51

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Published on: June 17, 2025

Treating IPF--all or nothing? A PRO-CON debate.

Jürgen Behr1, Martin Kolb, Gerard Cox

  • 1Division of Pulmonary Diseases, Department of Internal Medicine I, Ludwig-Maximilians University of Munich, 81377 Munich, Germany. juergen.behr@med.uni-muenchen.de

Respirology (Carlton, Vic.)
|November 14, 2009
PubMed
Summary
This summary is machine-generated.

This review debates the use of anti-inflammatory and antioxidant therapies for Idiopathic Pulmonary Fibrosis (IPF), a progressive lung disease. Evidence for their benefit in IPF management remains inconclusive, prompting a discussion of pros and cons.

More Related Videos

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis
06:59

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis

Published on: August 26, 2025

Related Experiment Videos

Last Updated: Jun 18, 2026

Refined Murine Model of Idiopathic Pulmonary Fibrosis
07:51

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Published on: June 17, 2025

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis
06:59

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis

Published on: August 26, 2025

Area of Science:

  • Pulmonology
  • Fibrotic Lung Diseases
  • Inflammation Research

Background:

  • Idiopathic Pulmonary Fibrosis (IPF) is a progressive, fatal lung disease.
  • IPF is histopathologically defined by usual interstitial pneumonia (UIP) patterns.
  • Significant inflammation is typically absent in IPF.

Purpose of the Study:

  • To review arguments for and against anti-inflammatory and antioxidant therapies in IPF.
  • To present a debate on the clinical utility of these treatments.
  • To provide a concluding statement on both therapeutic approaches.

Main Methods:

  • Literature review and synthesis of existing evidence.
  • Debate format presenting pro and con arguments.
  • Analysis of current IPF management guidelines.

Main Results:

  • Current IPF guidelines include anti-inflammatory therapy without strong recommendations.
  • Convincing evidence supporting the efficacy of anti-inflammatory and antioxidant therapies in IPF is lacking.
  • The role of inflammation in IPF pathogenesis is debated.

Conclusions:

  • The efficacy of anti-inflammatory and antioxidant therapies for IPF requires further investigation.
  • A balanced perspective on the potential benefits and limitations of these treatments is necessary.
  • Evidence-based recommendations for IPF management are crucial.